These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

370 related items for PubMed ID: 24934637

  • 21. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
    Semiglazov V, Eiermann W, Zambetti M, Manikhas A, Bozhok A, Lluch A, Tjulandin S, Sabadell MD, Caballero A, Valagussa P, Baselga J, Gianni L.
    Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
    [Abstract] [Full Text] [Related]

  • 22. Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial.
    Partridge AH, Gelber S, Piccart-Gebhart MJ, Focant F, Scullion M, Holmes E, Winer EP, Gelber RD.
    J Clin Oncol; 2013 Jul 20; 31(21):2692-8. PubMed ID: 23752109
    [Abstract] [Full Text] [Related]

  • 23. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
    Cadoo KA, Morris PG, Cowell EP, Patil S, Hudis CA, McArthur HL.
    Clin Breast Cancer; 2016 Dec 20; 16(6):487-493. PubMed ID: 27622751
    [Abstract] [Full Text] [Related]

  • 24. Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival.
    Rossi M, Carioli G, Bonifazi M, Zambelli A, Franchi M, Moja L, Zambon A, Corrao G, La Vecchia C, Zocchetti C, Negri E.
    Eur J Cancer; 2016 Jan 20; 52():41-9. PubMed ID: 26630533
    [Abstract] [Full Text] [Related]

  • 25. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).
    Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, Láng I, Wardley A, Lichinitser M, Sanchez RI, Müller V, Dodwell D, Gelber RD, Piccart-Gebhart MJ, Cameron D.
    Lancet Oncol; 2013 Mar 20; 14(3):244-8. PubMed ID: 23414588
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.
    Pernas S, Gil-Gil M, de Olza MO, Gumà A, Climent F, Petit A, Pla MJ, García-Tejedor A, López-Ojeda A, Falo C, Fernandez-Otega A, Mesia C, Pérez-Martin FJ, Urruticoechea A, Germà JR.
    Breast Cancer Res Treat; 2012 Aug 20; 134(3):1161-8. PubMed ID: 22772380
    [Abstract] [Full Text] [Related]

  • 27. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
    Rossi V, Nolè F, Redana S, Adamoli L, Martinello R, Aurilio G, Verri E, Sapino A, Viale G, Aglietta M, Montemurro F.
    Breast; 2014 Feb 20; 23(1):44-9. PubMed ID: 24210572
    [Abstract] [Full Text] [Related]

  • 28. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
    Horiguchi J, Oyama T, Takata D, Rokutanda N, Nagaoka R, Odawara H, Tokiniwa H, Tozuka K, Kikuchi M, Sato A, Takeyoshi I.
    Anticancer Res; 2011 Sep 20; 31(9):3041-6. PubMed ID: 21868556
    [Abstract] [Full Text] [Related]

  • 29. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
    Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL.
    J Clin Oncol; 2009 Dec 01; 27(34):5685-92. PubMed ID: 19884557
    [Abstract] [Full Text] [Related]

  • 30. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M, Sasaki M, Shimomura A, Fujishima M, Doi M, Matsuura K, Sakuma T, Yoshimura K, Saeki T, Ohara M, Tsurutani J, Watatani M, Takano T, Kawabata H, Mukai H, Naito Y, Hirokaga K, Takao S, Minami H.
    Breast; 2014 Aug 01; 23(4):466-72. PubMed ID: 24742606
    [Abstract] [Full Text] [Related]

  • 31. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
    Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ, HERA study team.
    Lancet; 2007 Jan 06; 369(9555):29-36. PubMed ID: 17208639
    [Abstract] [Full Text] [Related]

  • 32. The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.
    Gori S, Inno A, Fiorio E, Foglietta J, Ferro A, Gulisano M, Pinotti G, Gubiotti M, Cavazzini MG, Turazza M, Duranti S, De Simone V, Iezzi L, Bisagni G, Spazzapan S, Cavanna L, Saggia C, Bria E, Cretella E, Vici P, Santini D, Fabi A, Garrone O, Frassoldati A, Amaducci L, Saracchini S, Evangelisti L, Barni S, Gamucci T, Mentuccia L, Laudadio L, Zoboli A, Marchetti F, Bogina G, Lunardi G, Boni L.
    PLoS One; 2015 Jan 06; 10(9):e0136731. PubMed ID: 26340098
    [Abstract] [Full Text] [Related]

  • 33. Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.
    Carvajal-Hausdorf DE, Schalper KA, Pusztai L, Psyrri A, Kalogeras KT, Kotoula V, Fountzilas G, Rimm DL.
    J Natl Cancer Inst; 2015 Aug 06; 107(8):. PubMed ID: 25991002
    [Abstract] [Full Text] [Related]

  • 34. Prognostic factors for recurrence-free survival in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab.
    Tonyali O, Coskun U, Sener N, Inanc M, Akman T, Ulas A, Yazilitas D, Bal O, Kucukoner M, Yildirim Ozdemir N, Demirci U, Gunaydin Y, Yildiz R, Karaca H, Umit Unal O, Gumus M, Benekli M, Buyukberber S.
    Onkologie; 2013 Aug 06; 36(10):554-8. PubMed ID: 24107908
    [Abstract] [Full Text] [Related]

  • 35. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
    Garrison LP, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA.
    Cancer; 2007 Aug 01; 110(3):489-98. PubMed ID: 17592827
    [Abstract] [Full Text] [Related]

  • 36. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
    Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J.
    J Clin Oncol; 2012 Jul 20; 30(21):2585-92. PubMed ID: 22689807
    [Abstract] [Full Text] [Related]

  • 37. Real-world outcomes of different treatments in the management of patients with HER-2 positive breast cancer: a retrospective study.
    Chitapanarux I, Trakultivakorn H, Srisukho S, Somwangprasert A, Watcharachan K, Srikawin J, Chaiwun B, Traisathit P.
    J Med Assoc Thai; 2013 Jun 20; 96(6):709-15. PubMed ID: 23951829
    [Abstract] [Full Text] [Related]

  • 38. Current and future anti-HER2 therapy in breast cancer.
    Vrbic S, Pejcic I, Filipovic S, Kocic B, Vrbic M.
    J BUON; 2013 Jun 20; 18(1):4-16. PubMed ID: 23613383
    [Abstract] [Full Text] [Related]

  • 39. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
    Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP.
    N Engl J Med; 2015 Jan 08; 372(2):134-41. PubMed ID: 25564897
    [Abstract] [Full Text] [Related]

  • 40. Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab.
    Ohzawa H, Sakatani T, Niki T, Yasuda Y, Hozumi Y.
    Breast Cancer; 2014 Sep 08; 21(5):563-70. PubMed ID: 23108629
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.